Introduction
Two different NF-B pathways have been identified that lead to transcription from B sites, and are referred to as the canonical and noncanonical (or alternative) pathways (Beinke and Ley, 2004; Bonizzi and Karin, 2004; Hayden and Ghosh, 2008; Vallabhapurapu and Karin, 2009 ). The canonical NF-B pathway is activated following stimulation with a broad range of stimuli such as TNF, IL-1, lipopolysaccharide (LPS) and genotoxic agents, and has a major role in the control of innate immunity and inflammation (Beinke and Ley, 2004; Bonizzi and Karin, 2004; Hayden and Ghosh, 2008; Vallabhapurapu and Karin, 2009 ). The canonical pathway involves phosphorylation of IB by IB kinase (IKK) components (primarily IKK) and subsequent degradation of IB, which typically holds the RelA-p50 heterodimer in the cytoplasm. IB degradation allows NF-B to translocate to the nucleus where it binds to B sites, leading to gene transcription (Beinke and Ley, 2004; Bonizzi and Karin, 2004; Hayden and Ghosh, 2008; Vallabhapurapu and Karin, 2009 ).
The noncanonical NF-B pathway is activated by particular TNF receptor family members that bind to the TNF receptorassociated factors TRAF2 and/or TRAF3, such as LTR, CD40, CD27, CD30, BAFF-R and RANK, which are mainly involved in secondary lymphoid organ development, B cell survival and maturation and osteoclastogenesis (Beinke and Ley, 2004; Bonizzi and Karin, 2004; Hayden and Ghosh, 2008; Vallabhapurapu and Karin, 2009 ). The noncanonical pathway requires IKK-dependent NF-B2 (p100) processing in the proteasome to generate p52. p52 is associated with RelB and enters the nucleus and binds to B sites in certain NF-B-responsive genes to activate transcription (Dejardin et al., 2002; Senftleben et al., 2001; Xiao et al., 2001) . Processing of p100 requires its phosphorylation by IKK, which in turn requires phosphorylation by NF-B-inducing kinase (NIK) (Senftleben et al., 2001; Xiao et al., 2004; Xiao et al., 2001) . Rapid turnover of NIK prevents constitutive activation of the noncanonical NF-B pathway in resting cells (Liao et al., 2004) . Most current data in the literature with regard to stimuli-dependent stabilization of NIK are consistent with a simple model (Zarnegar et al., 2008; Vallabhapurapu et al., 2008) , in which TRAF3 recruits NIK to a complex containing TRAF2 and inhibitor of apoptosis proteins cIAP1 and/or cIAP2 (cIAP1/2), where NIK ubiquitylation by cIAP1 or cIAP2 promotes its proteasomal degradation. The role of TRAF2 in this complex is to recruit TRAF3 and the cIAP proteins through direct interactions. This model predicts that the loss of TRAF2, TRAF3 or both cIAP1 and cIAP2 would lead to noncanonical NF-B activation by the resulting stabilization of the NIK protein. Thus, cells deficient in TRAF2 or TRAF3 have high basal levels of NIK and p52 (Gardam et al., 2008; Grech et al., 2004; He et al., 2007; He et al., 2006; Vallabhapurapu et al., 2008; Xie et al., 2007) , whereas inhibition of cIAP proteins by smallmolecule antagonists results in activation of the noncanonical NF-B pathway in a manner that is dependent on NIK stabilization, thereby enhancing B lymphocyte survival and proliferation (Varfolomeev et al., 2007; Vince et al., 2007) . High levels of NIK and p52 in multiple myelomas might also be explained by several
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The current paradigm of noncanonical NF-B signaling suggests that the loss of TRAF2, TRAF3 or cIAP1 and cIAP2 leads to stabilization of NF-B-inducing kinase (NIK) to activate the noncanonical pathway. Although a crucial role of RIP1 in the TNF-induced canonical NF-B pathway has been well established, its involvement in noncanonical activation of NF-B through the TNFR1 receptor, is unknown. Here we show that TNF is capable of activating the noncanonical NF-B pathway, but that activation of this pathway is negatively regulated by RIP1. In the absence of RIP1, TNFR1 stimulation leads to activation of the noncanonical NF-B pathway through TRAF2 degradation, leading to NIK stabilization, IKK phosphorylation and the processing of p100 to generate p52. Thus although RIP1 -/-mouse embryonic fibroblasts are sensitive at early time points to cell death induced by TNF, probably as a result of lack of canonical NF-B activation, the late activation of the noncanonical NF-B pathway protects the remaining cells from further cell death. The TNFR1-dependent noncanonical NF-B activation in RIP1 -/-cells suggests that there is functional interplay between the two NF-B pathways during TNFR1 signaling, which might regulate the number and kinds of NF-B transcription factors and thus finely control NF-B-dependent gene transcription. different genetic alterations, including deletion of TRAF2 or TRAF3 or bi-allelic deletions of both cIAP1 and cIAP2 (Annunziata et al., 2007; Keats et al., 2007) . However, very few receptormediated stimuli have been described that cause noncanonical activation dependent solely upon degradation of TRAF2 in the absence of TRAF3 degradation.
Receptor-interacting protein 1 (RIP1) has emerged as an essential molecule that is involved in death receptor signaling and cellular stress (Festjens et al., 2007) . The C-terminal death domain of RIP1 is capable of binding to death receptors with a similar death domain motif in death receptors, such as TNFR1 and Fas, and the TRAIL (TNF-related apoptosis-inducing ligand) receptors (Chaudhary et al., 1997) , and also interacts with other death domain-containing adaptor proteins, such as TRADD (TNFR1-associated DEATH domain protein) and FADD (FAS-associated death domain protein) (Varfolomeev et al., 1996) . As a TRADD-and TNFR1-binding molecule, RIP1 is a key effector molecule in the TNF-induced activation of the transcription factor NF-B (Kelliher et al., 1998) . This is largely because the Lys63-linked polyubiquitylation of RIP1 by cIAP1/2 (Lin et al., 2010) leads to its interaction with regulatory subunit of the IKK complex, IKK-NEMO, and thus RIP1 is essential for robust TNF activation of IKK and of the canonical NF-B pathway (Ea et al., 2006; Poyet et al., 2000; Wu et al., 2006) . Although RIP1 has a role in death receptor apoptosis (Morgan et al., 2009; O'Donnell et al., 2007; Wang et al., 2008) , it is essential for death receptor-mediated necrotic cell death by Fas and TNF (Holler et al., 2000; Lin et al., 2004) , where it is required for the generation of reactive oxygen species (ROS) (Lin et al., 2004) . We have recently reported that RIP1 and TRADD interact with NOXO1 to recruit and activate the NADPH oxidase Nox1, resulting in superoxide production during TNF-induced necrotic cell death . Therefore, RIP1 is a crucial component of TNF signaling that controls the divergence of distinct pathways and cellular outcomes in TNF-exposed cells. However, the involvement of RIP1 in the noncanonical NF-B pathway has not been examined.
Our previous studies demonstrated that TRAF2, which is an important effector molecule of TNF signaling, is also a crucial, non-redundant component in LTR signaling (Kim et al., 2005) . However, we found that RIP1 is not involved in LTR-mediated activation of NF-B and JNK (Kim et al., 2005 ). In the current study, we found that RIP1 is a negative regulator of the noncanonical NF-B pathway in TNFR1 signaling. The absence of RIP1 in cells treated with TNFleads to TRAF2 degradation, NIK stability, phosphorylation of IKK and p100 processing, resulting in noncanonical NF-B activation.
Results

TNF activates the noncanonical NF-B pathway in RIP1 -/-
MEFs
Although a crucial role of RIP1 in the canonical TNF-induced NF-B pathway has been well established (Devin et al., 2000; Ea et al., 2006; Kelliher et al., 1998; Poyet et al., 2000; Wu et al., 2006) , its involvement in noncanonical NF-B activation is unknown. We carefully compared TNF-induced p100 processing in MEF cells and found that treatment with murine TNF led to a significant increase in processing of p100 and the formation of p52 in RIP1 -/-mouse embryonic fibroblasts (MEFs), but not in wildtype (WT) MEFs (Fig. 1A) . Unlike canonical NF-B activation, the TNF-induced processing of p100 in these cells appears slowly and only becomes evident after 4 hours. We treated the RIP1 -/-MEFs with human recombinant TNF, which only binds to TNFR1 in murine cells (Lewis et al., 1991) . A similar pattern of p100 processing was observed when treated with human TNF (supplementary material Fig. S1A ), suggesting that p52 generation is mediated by TNFR1, but not TNFR2. Similar results were obtained in RIP1 -/-MEFs treated with an agonistic TNFR1-specific antibody (supplementary material Fig. S1B ), and the p52 to p100 ratio decreased substantially at the 4-hour time point when a TNFR1-specific blocking antibody was added (Michael Morgan, unpublished results). Next, we compared the role of RIP1 in early
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Journal of Cell Science 124 (4) TNF-induced NF-B activation, which is proposed to be solely mediated by the canonical pathway (Rauert et al., 2009 ) and LTR-induced NF-B activation, which substantially activates the noncanonical pathway (Dejardin et al., 2002) . TNF treatment led to potent NF-B activation in WT MEFs, with a partial reduction in TRAF2 -/-MEFs and little activation in RIP1 -/-MEFs, as determined by electrophoretic mobility shift assay (EMSA) at early time points (Fig. 1B) . Some activation by EMSA was observed in RIP1 -/-MEFs at high exposure. Nevertheless, this activation was substantially less than in WT cells. Since a recent report has questioned the role of RIP1 in early canonical NF-B activation using different methodology (Wong et al., 2010) , we also looked at IB degradation in the same cells. IB degradation was substantially decreased in RIP1 -/-cells when compared with WT cells (Fig. 1C) . Because our MEFs were immortalized after going through crisis, we wanted to verify that the effect was due to loss of RIP1 and not other molecules. We therefore stably transfected FLAG-RIP1 into the RIP1 -/-MEFs and observed that IB degradation was restored when RIP1 expression was reconstituted (Fig. 1D ). In addition, siRNA knockdown of RIP1 in WT MEFs also led to a decrease in IB degradation (Fig. 1E ). This data suggests that although RIP1 might not be absolutely required for any TNF-induced canonical NF-B activation per se, it has a significant and positive role in this process. By contrast, and consistent with our previous finding (Kim et al., 2005) , LTR-mediated noncanonical NF-B activation was similar in WT and RIP1 -/-MEFs (supplementary material Fig. S1C ), suggesting that RIP1 is not important in the noncanonical NF-B activation initiated through the LT receptor. Taken together, these results suggest that RIP1 is required for activation of the canonical pathway by TNFR1 and it might negatively affect activation of the noncanonical pathway specifically through TNFR1 when the cells are treated with TNF.
TNF induces TRAF2 degradation in RIP1 -/-MEFs
The noncanonical NF-B pathway is constitutively active in TRAF2 -/-B cells and MEFs (Grech et al., 2004; Vince et al., 2007) , and is degraded upon CD40 engagement in B cells (Brown et al., 2001; Liao et al., 2004) , suggesting that TRAF2 functions as a negative regulator of p100 processing. We therefore carefully examined TRAF2 protein levels in TNF-treated RIP1 -/-MEFs. Upon TNF treatment, there was marked reduction of TRAF2 in RIP1 -/-MEFs, but not in WT MEFs ( Fig. 2A and supplementary material Fig. S2 ). Notably, reduction of TRAF2 protein levels in RIP1 -/-MEFs correlated with p100 processing, whereas p52 protein levels were constitutively higher in TRAF2 -/-MEFs, irrespective of TNF treatment. A closer kinetic study revealed that TRAF2 degradation began 30 minutes after TNF treatment and TRAF2 levels continued to decrease until 4 hours after treatment, which is when we observed processing of p100 to p52 (Fig. 2B ). Treatment with both murine and human TNF led to a reduction in TRAF2 protein levels to the same extent, suggesting that TNF-induced reduction of TRAF2 is mediated by TNFR1 (supplementary material TRAF3 is degraded upon engagement of BAFF-R or CD40, and its degradation is therefore thought to be important in activation of the noncanonical NF-B pathway (Brown et al., 2001; Liao et al., 2004) . TRAF3-deficient cells show constitutive processing of p100 to p52 (Gardam et al., 2008) . However, we failed to observe much change in TRAF3 protein levels in TNF-treated RIP1 -/-MEFs (Fig. 2C ). We previously saw little change in TRAF3 protein levels during noncanonical NF-B activation induced by anti-LTR antibody (Kim et al., 2005) . Therefore, although TRAF3 degradation might be involved in noncanonical NF-B activation downstream of some TNF receptor family members in certain cell types, it appears to not be required for activation of the noncanonical 649 RIP1 attenuates noncanonical NF-B pathway downstream of TNFR1 or LTR in MEFs, and it is TRAF2 degradation that is associated with the TNF-induced activation of the noncanonical NF-B pathway in the RIP1 -/-MEFs. To verify that TRAF2 degradation and noncanonical NF-B activation in the RIP1 -/-MEFs is the authentic effect of RIP1 deficiency, we first used siRNA to knock down RIP1 in wild-type MEFs, and verified that TRAF2 degradation accompanied RIP1 deficiency in TNF-treated cells (Fig. 2D) . We next examined the effect of RIP1 reconstitution in RIP1 -/-MEFs in response to TNF treatment. Transfection of FLAG-tagged RIP1 into RIP1 -/-MEFs restored the RIP1 protein level to endogenous levels (Fig. 2E) . Reconstitution of RIP1 blocked TRAF2 degradation and significantly reduced processing of p100 that was induced by TNF (Fig. 2F) , supporting the notion that RIP1 negatively regulates noncanonical NF-B activation in response to TNF treatment by preventing TRAF2 degradation.
To further substantiate the role of RIP1 in prevention of noncanonical NF-B activation, we infected A549 lung cancer cells with a lentivirus expressing RIP1 shRNA. When RIP1 was knocked down, TNF-induced p100 processing to p52 was clearly detected (Fig. 3A) , confirming that TNF-stimulated activation of the noncanonical pathway is not restricted to MEFs, and that RIP1 negatively regulates this pathway. TNF-stimulated NF-B activity as measured by a NF-B luciferase reporter was significantly reduced in the RIP1-knockdown cells (Fig. 3B) ; however, some the remaining NF-B activity was additionally reduced by transfection of IKK siRNA to block noncanonical NF-B activation (Fig. 3B ). Since IKK is required upstream of the noncanonical pathway, this probably indicates that at least some of the remaining NF-B activity in the RIP1-deficient cells is attributable to activation of the noncanonical pathway. No reduction in NF-B-driven activity was seen in control cells transfected with IKK siRNA, suggesting that the noncanonical pathway is activated only in the absence of RIP1.
Degradation of TRAF2 leads to accumulation of NIK
We next examined the signaling events downstream of TRAF2 degradation. Activation of the noncanonical NF-B pathway requires NF-B-inducing kinase (NIK) activity to induce p100 processing (Xiao et al., 2004) . TRAF3 recruits NIK to a complex that promotes its proteasomal-mediated degradation, whereas TRAF2 recruits cIAP1 or cIAP2, which are necessary for the degradation to take place (Vallabhapurapu et al., 2008; Zarnegar et al., 2008) . Therefore, we hypothesized that TRAF2 degradation should lead to the stabilization of NIK and the subsequent activation of the noncanonical NF-B pathway. TNF did induce NIK accumulation in RIP1 -/-MEFs, whereas no increase occurred in WT MEFs (Fig. 4A) . As expected, NIK protein levels were high in TRAF2
-/-MEFs, even in the absence of TNF (Fig. 4A ). To verify that this was a TNFR1-specific effect, we treated RIP1 -/-MEFs with an agonistic TNFR1-specific antibody (supplementary material Fig. S4A ) and NIK accumulated similarly as with TNF treatment. To further eliminate the effect of TNFR2, we transfected TNFR2 -/-MEFs with siRNA to knock down RIP1 and treated these cells with TNF. We observed NIK accumulation in these cells at 1 and 4 hours after TNF treatment (supplementary material Fig. S4B ). Because NIK activates IKK by phosphorylation to trigger p100 processing (Senftleben et al., 2001; Xiao et al., 2004; Xiao et al., 2001) , we looked at whether IKK is phosphorylated when NIK levels increase in the absence of RIP1. There was a transient increase in IKK phosphorylation in TNF-treated RIP1 -/-MEFs that followed the increase of NIK (Fig. 4B) . Although NIK stability usually peaked between 1and 4 hours, after that the NIK stability and the IKK phosphorylation decreased, and the levels of TRAF2 began to rise again. By 8 hours, NIK levels had
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Journal of Cell Science 124 (4) returned to that of the untreated cells despite the fact that the TRAF2 levels did not completely recover. This might suggest a secondary feedback inhibition on the stability of NIK in addition to TRAF2. Nevertheless, these results indicate that the degradation of TRAF2 in the absence of RIP1 precedes the appearance of NIK stabilization and phosphorylation of IKK, which precedes the generation of p52. Thus TRAF2 degradation is probably the crucial event that leads to the activation of the noncanonical NF-B pathway by TNF.
TRAF2 degradation in TNF-stimulated RIP1 -/-MEFs is blocked by proteasomal inhibition
Because our data indicate that TNF-induced degradation of TRAF2 is a crucial step in p100 processing in these cells, we examined the mechanism of TRAF2 degradation. Neither NIK stabilization and p52 generation, nor TRAF2 degradation was inhibited in the presence of cycloheximide (supplementary material Fig. S5A ), indicating that de novo protein synthesis is not required for induction of the upstream noncanonical pathway. TRAF2 degradation and p100 processing was likewise not affected by the pan-caspase inhibitor zVAD (supplementary material Fig. S5B ), indicating that caspases are not the source of cleavage or degradation. Although TRAF2 degradation in RIP1 -/-MEFs was not inhibited by zVAD, it was completely inhibited by MG132 (supplementary material Fig. S6A ), suggesting that the reduction of TRAF2 protein is due to proteasome-dependent degradation, rather than caspase-mediated cleavage. Stabilization of TRAF2 by MG132 treatment resulted in the suppression of p100 processing in response to TNF (supplementary material Fig. S6B ), which might further suggest that TRAF2 negatively regulates the TNF-induced noncanonical NF-B pathway in RIP1 -/-MEFs. However, p100 processing is thought to also be dependent on the proteasome, so we examined the effect of short-term MG132 treatment on the basal levels of p52 in TRAF2 -/-, TRAF2 -/-
TRAF5
-/-and TRAF3 -/-MEFs, which have constitutive p52 processing (supplementary material Fig.  S6C,D,E) . Short-term treatment of MG132 did not substantially reduce p52 levels in these cell types. Interestingly, although these cells have stable NIK levels because of a lack of TRAFs, the NIK protein was more highly upregulated in all of these cell types upon MG132 treatment (supplementary material Fig. S6C,D,E) , suggesting that NIK expression is tightly negatively controlled by other mechanisms in addition to the TRAF-dependent ubiquitylation that targets NIK to the proteasome. The increased NIK in the MG132-treated cells would be predicted lead to higher p52 generation. However, we saw no such generation, suggesting either that MG132 blocked additional p52 generation, or that maximal p52 generation was already occurring. These data would be consistent with the hypothesis of Demchenko and colleagues, who, based on results from multiple myeloma cell lines with mutant TRAF proteins, postulated that an initial NIK stabilization event substantially activates noncanonical NF-B, whereas further stabilization of NIK has little cumulative effect on NF-B activation (Demchenko et al., 2010) . These data indicate that although it is clear that TRAF2 is being degraded in a proteasomal-dependent manner in TNF-stimulated RIP1 -/-MEFs, because proteasomal inhibition can block both TRAF2 degradation and p100 processing, we could not conclude, based on these experiments, that p52 generation was dependent on TRAF2 degradation in this case. We therefore sought other data that would be consistent with this hypothesis.
RIP1 binding to the receptor complex limits the recruitment of TRAF2 to TNFR1
When stimulated, TNFR1 recruits adaptor proteins, such as TRADD, RIP1 and TRAF2 to the receptor complex at the cell membrane, which is then internalized as a whole to form secondary signaling complexes (Schneider-Brachert et al., 2004) . Although studies by our group and others have found that TRAF2 recruitment to TNFR1 is TRADD dependent, the binding of RIP1 within the TNFR1 complex does not absolutely require TRADD, but TRADD substantially enhances the RIP1 recruitment and is required for ubiquitylation of RIP1 in the complex (Ermolaeva et al., 2008; Pobezinskaya et al., 2008) . We performed co-immunoprecipitation experiments in WT and RIP1 -/-MEFs with an anti-TNFR1 antibody and examined the recruitment of TRAF2. Both TRAF2 and RIP1 were quickly recruited to TNFR1 following TNF treatment in WT MEFs (Fig. 5A) . In RIP1 -/-MEFs, TNF-induced TRAF2 recruitment was dramatically increased by nearly 100-fold, whereas the levels of TNFR1 protein precipitated were similar in both cell types (Fig. 5A ). The TRAF2 interaction was rapid and transient, reaching its peak at 5 minutes, whereas only a small fraction of TRAF2 was found interacting with TNFR1 at 30 minutes (Fig. 5A ). Also consistent with previous data (Devin et al., 2000) , there was an enhanced level of TRADD pulled down by TNFR1 in RIP1 -/-MEFs compared with levels in WT MEFs (Fig. 5A ), indicating that RIP1 might compete somewhat with TRADD in its interaction with TNFR1 in response to TNF. When co-immunoprecipitation experiments were performed with an anti-TRADD antibody, significantly more TRAF2 interacted with TRADD in RIP1 -/-MEFs than in WT MEFs (Fig. 5B) , suggesting that that RIP1 also limits RIP1 attenuates noncanonical NF-B TRAF2 recruitment to TRADD in response to TNF. Importantly, the level of ubiquitylation in the receptor complex increased considerably (supplementary material Fig. S7 ), and this corresponded with substantially higher levels of high molecular weight TRAF2 in the complex (Fig. 5 and supplementary material Fig. S7 ), indicating that TRAF2 is more highly ubiquitylated in the receptor complex in the RIP1 -/-MEFs, which is consistent with data in supplementary material Fig. S6 showing that the proteasome inhibition blocks TRAF2 degradation. These data thus suggest that RIP1 has a previously unidentified function: to limit the recruitment of TRAF2 to TNFR1, thus stabilizing TRAF2 levels and subsequently preventing the activation of the noncanonical NF-B pathway. To determine whether the kinase activity of RIP1 was important in preventing TRAF2, we transfected RIP1 -/-MEFs with kinasedeficient Xpress-RIP1 (K45A). Transfection of this plasmid decreased TRAF2 degradation, NIK stability and generation of p52 in response to TNF (supplementary material Fig. S8 ), although these decreases were not as substantial as in our previous experiment using nonmutant FLAG-RIP1 (Fig. 2F) . It is not clear whether this was due to less RIP1 transfection efficiency or expression, use of a different epitope tag or lack of kinase activity. Nevertheless, the partial protection seen in this experiment might indicate that the kinase activity of RIP1 is not required for its protection from TRAF2 degradation.
Noncanonical NF-B activation protects against TNF-induced death in RIP1
-/-MEFs RIP1 has important roles in death-receptor-induced cell death in both apoptosis and necrosis (Holler et al., 2000; Kim et al., 2007; Lin et al., 2004; Morgan et al., 2009; O'Donnell et al., 2007; Wang et al., 2008) . Owing to activation of the NF-B pathway, which results in production of pro-survival proteins, most cells are resistant to TNF in the absence of protein synthesis inhibitors. We examined TNF-induced cell death in the RIP1 -/-MEFs, which lack the strong canonical NF-B activation induced in WT MEFs (Kelliher et al., 1998) . As shown in Fig. 6A , TNF alone was sufficient to induce apoptotic cell death in RIP1 -/-MEFs at earlier time points (within 8 hours), but not in WT MEFs. Knockdown of RIP1 in wild-type cells also led to cell death from TNF alone (supplementary material Fig. S9A) , with corresponding cleavage of caspase-3 (supplementary material Fig. S9B ). Conversely, ectopic expression of FLAG-RIP1 in these cells decreased their sensitivity to TNF (supplementary material Fig. S9C ), indicating that RIP1 deficiency is the likely reason for cell death. In agreement with the cell cytotoxicity assay data, we detected caspase-3 cleavage in RIP1
-/-MEFs upon TNF treatment, but not in WT MEFs (Fig.  6B) . Surprisingly, when we treated these cells for 24 hours, we found that cell death did not increase after the 8-hour time point, as measured by LDH release (Fig. 6C) or morphological detection under a microscope (supplementary material Fig. S10 ). To confirm this phenomenon, we examined caspase-3 activation and PARP1 cleavage over a long time course. Caspase-3 activation increased until 4 hours after TNF treatment, and then decreased rapidly (Fig. 6D) . Consistently, PARP1 cleavage started at 1 hour and peaked at 4 hours after TNF treatment and then diminished, accompanying the reduction of caspsase-3 activity (Fig. 6E) . The kinetics of cell death and its subsequent reduction was verified by Annexin-V and propidium iodide staining (Fig. 6F ). This analysis showed that cell death peaked at about 4 hours and then was subsequently reduced. TNF-induced cell death was sensitized in the presence of CHX, whereas the pan-caspase inhibitor, z-VADfmk, completely blocked TNF-induced cell death (supplementary material Fig. S11 ). The necrosis inhibitor necrostatin-1 had no effect on cell death, indicating that only apoptotic cell death occurred, and consistent with the requirement of RIP1 in necrotic cell death and the fact that this drug acts as an inhibitor of RIP1 kinase activity (supplementary material Fig. S11 ).
The correlation of the decrease in caspase activation with the onset of strong p52 generation 4 hours after TNF treatment in RIP1 -/-cells suggests that the noncanonical NF-B pathway protects these cells from further apoptotic cell death, probably through induction of anti-apoptotic genes. To see whether this was the case, we used siRNA to prevent NIK expression in RIP1 -/-MEFs. NIK protein expression was effectively eliminated from occurring in cells transfected with NIK siRNA, although TRAF2 degradation continued to take place (Fig. 7A) . The prevention of NIK expression led to an increased sensitivity of the RIP1 -/-MEFs to TNF, especially at the 8 hour time point, as observed by light microscopy (Fig. 7B) or by LDH assay (Fig. 7C) , thus showing that the activation of the noncanonical NF-B pathway protected RIP1 -/-MEFs from TNF-induced cell death. As further evidence that this was the case, the pretreatment of these cells with LIGHT, a well-known inducer of noncanonical NF-B activation prevented RIP1 -/-MEFs from dying in response to TNF (Fig. 7D) . Thus, although RIP1 -/-MEFs undergo cell death early, as a result of RIP1 deficiency, the late activation of the noncanonical NF-B protects surviving cells from long-term TNF toxicity.
Discussion
We report here that TNFR1 is capable of activating the noncanonical NF-B signaling pathway in addition to the canonical pathway. Consistent with previous reports (Dejardin et al., 2002; Rauert et al., 2009) , our data suggest that under normal circumstances in MEF cells, TNF does not substantially activate this pathway through TNFR1. During TNFR1 signaling, the presence of RIP1 in the receptor complex not only serves to potentiate the canonical NF-B pathway, but also prevents activation of the noncanonical NF-B pathway. RIP1 limits the amount of TRADD and TRAF2 proteins recruited to the TNFR1 signaling complex, probably limiting extensive ubiquitylation of TRAF2 in the receptor complex. When RIP1 is removed, ubiquitylation-dependent and proteasomal-mediated TRAF2 degradation leads to NIK stabilization and subsequently the activation of the noncanonical pathway. From the data in our study, we propose that RIP1 deficiency leads to a lack of canonical NF-B upon TNF treatment. This sensitizes the cells to cell death at earlier time points. However, as a result of the lack of RIP1, TRAF2 is degraded and NIK is stabilized, leading to noncanonical NF-B activation, and thus protecting the cells from further death.
RIP1 has a weak binding affinity to TRAF2 through its kinase and intermediate domains (Hsu et al., 1996) , suggesting a possible direct interaction between RIP1 and TRAF2 while in the complex. Because it has a strong affinity for RIP1, TRADD enables the efficient recruitment RIP1 to the TNFR1 receptor complex (Ermolaeva et al., 2008; Pobezinskaya et al., 2008) . However, in the absence of TRADD, RIP1 maintains a weak interaction with TNFR1, suggesting that there is also a direct interaction between 653 RIP1 attenuates noncanonical NF-B RIP1 and TNFR1 (Chen et al., 2008; Ermolaeva et al., 2008; Pobezinskaya et al., 2008) . Our data here show that loss of this interaction (through a RIP1 deficiency) permits greater TRADD recruitment to TNFR1. The comparative amount of TRAF2 increase in the receptor complex is even proportionally greater than the increase in TRADD when compared with levels in WT cells. Therefore, it seems likely that RIP1 is not only competing to some extent with TRADD for TNFR1 binding, but also slows or obstructs TRAF2 binding to TRADD, perhaps by a kinetic constraint that is imposed by forming its own associations with TRADD and TRAF2.
In the absence of RIP1, not only was more TRAF2 recruited to TNFR1 complex, but also a greater abundance of higher molecular weight TRAF2 was found in the receptor complex, suggesting that TRAF2 is further ubiquitylated, thus increasing TRAF2 protein degradation. Since cIAP proteins are recruited by TRAF2 to the TNFR1 complex and TRAF2 is degraded by cIAP1 during TNFR2 signaling Rothe et al., 1995; Shu et al., 1996) , we hypothesize that the loss of RIP1 results in less competition for cIAP activity, and therefore more TRAF2 ubiquitylation. Without RIP1, cIAP proteins might also be in a less spatially constrained environment, and therefore the enzymatic sites might be able to better interact structurally and therefore more substantially ubiquitylate TRAF2.
The absence of RIP1 in the complex probably prevents the formation of a full IKK complex consisting of all the subunits (i.e. IKK, IKK, IKK), which is necessary for the full activation of the canonical pathway. We have previously shown that IKK and IKK can be recruited to an activated TNFR1 complex in the absence of IKK through interaction with TRAF2 (Devin et al., 2000; Devin et al., 2001 ). However, others have shown that the polyubiquitylated RIP1-recruited IKK subunit strongly stabilizes complex formation (Ea et al., 2006; Poyet et al., 2000; Wu et al., 2006) . Although an absolute primary role for RIP1 in activation of the canonical pathway has been recently questioned (Wong et al., 2010) based on observation of IB degradation and analysis of gene expression in response to TNF, in our hands, the deficiency of RIP1 in RIP1 -/-MEFs or by RIP1 knockdown leads to a significant decrease in TNF-induced IB degradation and NF-B binding as measured by EMSA, which is in agreement with numerous previous studies. Because less IKK is tied up in the canonical pathway, more IKK might be free to form IKK homodimers to activate the noncanonical pathway downstream of NIK (Senftleben et al., 2001) . Inhibition of the regulatory IKK subunit binding using peptide inhibitors has previously been shown to increase the basal level of IKK activity (May et al., 2000) . Thus, RIP1 deficiency could conceivably contribute to noncanonical activation in two different ways. Consistent with our current data regarding TRAF3 expression in TNF-treated RIP1
-/-cells, we previously reported little change in TRAF3 protein levels in response to LIGHT-induced activation of the noncanonical NF-B pathway (Kim et al., 2005) . However, we observed extensive TRAF2 degradation during TNFR1 activation, but not during LIGHT signaling (Kim et al., 2005) . These two pathways are therefore distinctly different from those of BAFF and CD40, where TRAF3 is degraded (Brown et al., 2001; Liao et al., 2004) . BAFF does not cause TRAF2 degradation, whereas CD40 stimulation results in loss of both TRAF2 and TRAF3 (Brown et al., 2001; Liao et al., 2004) . However, TWEAK signaling through its receptor, FN14, activates a lysosome-mediated degradation of TRAF2 and cIAP1 in a cIAP1-dependent manner, and thus activates the noncanonical pathway (Vince et al., 2008) . Consistent with this, our data also indicate that TRAF2 degradation, as induced by a receptor stimulus, is sufficient for activation of the noncanonical pathway. Based on our data, and the current model, one would predict that TNFR2 stimulation would result in the activation of the noncanonical pathway, because TRAF2 is degraded by cIAP1 during TNFR2 signaling . Consistent with our model, a new report has been published during the preparation of this manuscript showing that membrane-bound TNF can activate the noncanonical pathway in primary T-cells and cancer cell lines through its binding to TNFR2 (Rauert et al., 2009) .
Both TRAF2-and TRAF3-knockout mice die perinatally of uncontrolled noncanonical NF-B activation (He et al., 2006; Vallabhapurapu et al., 2008; Yeh et al., 1997) . In light of our data, and because RIP1 -/-mice have similar prenatal lethality (Kelliher et al., 1998 ) that is partially rescued by TNFR1 deficiency (Cusson et al., 2002) , it is possible that some of the defects in RIP1 -/-mice are also due, in part, to hyperactive noncanonical NF-B signaling downstream of TNF.
Previous reports have suggested that activation of the noncanonical pathway serves to downregulate the canonical pathway in different ways (Basak et al., 2007; Lawrence et al., 2005) . Our studies show that TNFR1 is capable of inducing both canonical and noncanonical pathways, but that both pathways are deliberatively regulated in opposite ways by RIP1. Thus, there is a functional interplay between the two pathways, which might allow regulation of the number and kinds of NF-B transcription factors and thus fine-tuning the regulation of NF-B-dependent genes. The canonical pathway is clearly the dominant NF-B pathway that ensures an early response of cells to TNF stimulation, whereas the noncanonical pathway might serve as a compensatory redundant mechanism. It is possible that when the canonical pathway is suppressed, the non-canonical pathway is activated to maintain a certain level of NF-B activity. For example, in some embryonic developmental stages, the canonical pathway is inactivated in certain organs when RIP1 expression is lost (Wong et al., 2010) . Although our results demonstrate that the noncanonical pathway is a pro-survival signal that protects cells from TNFinduced cytotoxicity, it would be interesting to determine whether this pathway has other biological roles during the TNF response.
Materials and Methods
Reagents.
Recombinant murine and human TNF, mouse recombinant TRAIL, human recombinant LIGHT, agonistic (AF-425-PB) and blocking (MAB430) TNFR1 antibodies, TRAF2 antibody and zVAD were purchased from R&D Systems. TRAF3, Sp-1, TRADD, ubiquitin and IB antibodies were purchased from Santa Cruz. RIP1 antibody was purchased from Transduction Laboratories. Caspase3 and PARP1 antibodies were purchased from Pharmingen. NIK, phospho-IKK, p52 and IKK antibodies were purchased from Cell Signaling. MG132 and CHX were purchased from Calbiochem. Agonistic monoclonal anti-murine lymphotoxin  receptor (LTR) antibody was kindly provided by J. Browning (Biogene). Actin and FLAG antibodies and Necrostatin-1 were purchased from Sigma.
Cell culture
Wild-type (WT), RIP1
-/-and TRAF2 -/-mouse embryonic fibroblast (MEF) cells were previously described (Kelliher et al., 1998; Yeh et al., 1997) . MEFs were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. RIP1 -/-(FLAG-RIP1) stable cell lines were established by transfecting cells with the designated vector and then maintaining in medium containing 10 g/ml puromycin. A549/NF-B-luc cells were purchased from Panomics (Fremont, CA), maintained in RPMI 1640 medium supplemented with 100 g/ml hygromycin, and were infected with GIPZ-RIP1 shRNA or negative control shRNA lentivirus (Open Biosystems, Huntville, AL). The puromycin-resistant cell clones were selected with puromycin (2 g/ml) medium and verified by RIP1 antibody by western blot, and were designated as A549/RIP1 KD (for EIP knockdown) and A459/NC (for negative control). They were maintained in RPMI 1640 with hygromycin (100 g/ml) and puromycin (2 g/ml).
Western blot analysis and co-immunoprecipitation
Upon treatment, cells were lysed in 0.5% NP-40 Tris M2 buffer . Equal amounts of cell extracts were resolved by 12% SDS-PAGE and analyzed by western blot. For immunoprecipitation assays, lysates were mixed and precipitated with antibody and protein-A-Sepharose or protein-G-Agarose beads by incubation at 4°C. The bound proteins were removed by boiling in SDS buffer and resolved in 12% SDS-polyacrylamide gels for western blot analysis and visualized by enhanced chemiluminescence (ECL, Amersham).
Electrophoretic mobility shift assay
Nuclear extracts were prepared and analyzed as previously described (Kim et al., 2005) . For the binding reaction, 5 g of nuclear extract was incubated at room temperature for 20 minutes with reaction buffer containing 20 mM HEPES (pH 7.9), 50 mM KCl, 0.1 mM EDTA, 1 mM DTT, 5% glycerol, 200 g/ml BSA, and 2 g poly(dI-dC)·poly(dI-dC). Then the 32 P-labeled double-stranded oligonucleotide (1 ng, ≥1ϫ10 5 c.p.m.) containing the NF-B binding consensus sequence (5Ј-GGCAA -CTGGGGACTCTCCCTTT-3Ј) was added to the reaction mixture for an additional 10 minutes at room temperature. The reaction products were fractionated on a nondenaturating 5% polyacrylamide gel, which was then dried and subjected to autoradiography. As controls of nuclear protein content, an anti-Sp1 antibody was used in EMSA and western blotting, respectively.
Transfection
Cells were transfected with FLAG-RIP1 plasmid , Xpress-RIP1K45A mutant plasmid, FLAG-TRAF2(87-501) or FLAG empty vector with Lipofectamine PLUS reagent according to the manufacturer's protocol (GIBCO/BRL).
siRNA knockdown
MEF cells were plated in six-well plates, and cells were transfected with 100 pmoles of NIK, RIP1 or non-targeting control (NC) RNAi oligo (Dharmacon) using Lipofectamine 2000 reagent (Invitrogen). After 48 hrs, cells were treated with TNF- for indicated times.
Luciferase assay
IKK siRNA was transfected with INTERFERin TM (PolyPlus Transfection, San Marcos, CA). After 48 hours, cells were treated with TNF as described in figure legends, lysed, and luciferase activity was measured using a luciferase assay kit (Promega Corporation, Madison, WI) and normalized to protein concentration.
Cytotoxicity assays
Cell death was determined using tetrazolium dye colorimetric test (MTT test) and absorbance read at 570 nm. LDH leakage was quantified using a cytotoxicity detection kit (Promega). Cell death was also measured by using a FITC-Annexin V Apoptosis Detection kit (BD Pharmingen) according to the manufacturer's manual. Representative images were also taken by a phase-contrast microscope.
